Ulobetasol propionate
Clinical data
Trade namesUltravate, Lexette, Bryhali
Other namesHalobetasol propionate, halobetasol propionate (USAN US)
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa601060
Routes of
administration		Topical
Drug classCorticosteroid; Glucocorticoid
ATC code
Legal status
Legal status
Identifiers
  • [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
CAS Number
PubChem CID
DrugBank
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.211.977
Chemical and physical data
FormulaC25H31ClF2O5
Molar mass484.96 g·mol−1
3D model (JSmol)
  • CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl
  • InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1
  • Key:BDSYKGHYMJNPAB-LICBFIPMSA-N

Ulobetasol propionate, also known as halobetasol propionate and sold under the brand name Ultravate among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.

It was patented in 1975 and approved for medical use in 1990.[1][2]

References

  1. ↑ "Ultravate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 29 April 2020.
  2. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 487. ISBN 9783527607495.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.